Biogen Idec and Elan Announce Webcast to Discuss Antegren Accounting.CAMBRIDGE, Mass. & SAN DIEGO, Calif. & DUBLIN -- Biogen Idec Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIIB BIIB Basic Imagery Interpretation Brief ) and Elan Corporation, plc (NYSE NYSE See: New York Stock Exchange : ELN) will host a conference call for the investment community at 8.00am ET / 1:00pm GMT on Wednesday, November 3, 2004. Peter Kellogg, Biogen Idec's CFO See Chief Financial Officer. , and Shane Cooke, Elan's CFO, will review the accounting methodology for ANTEGREN(R) (natalizumab). The live webcast is accessible through Biogen Idec's website, www.biogenidec.com and Elan's website, www.elan.com. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. About Elan Elan is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing, selling and marketing advanced therapies in neurodegenerative diseases, autoimmune diseases and severe pain. Elan's shares trade on the New York, London and Dublin Stock Exchanges. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion